JO
CYT

John Overdeck’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

John Overdeck’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,093
Closed -$25K – 3153
2022
Q3 		$25K Sell
13,093
-11,269
-46% -$29.4K ﹤0.01% 2369
2022
Q2 		$73K Buy
24,362
+5,969
+32% +$15.2K ﹤0.01% 2310
2022
Q1 		$69K Buy
+18,393
New +$105K ﹤0.01% 2464

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

John Overdeck's CYT Position: Q4 2022 in Review

John Overdeck sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q4 2022, closing a stake of 13,093 shares — an estimated $25K sold.

John Overdeck first reported a position in CYT in Q1 2022 and held it in 3 quarters. The position peaked at $73K in Q2 2022. 30 funds tracked by Wall St. Rank hold CYT as of Q4 2022.

  • John Overdeck reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • John Overdeck sold 13,093 Cyteir Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $25K.
  • John Overdeck first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • John Overdeck's Cyteir Therapeutics, Inc. Common Stock position peaked at $73K in Q2 2022.
  • 30 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Two Sigma Investments's 13F filing for Q4 2022, filed 14 Feb 2023.